Final two-year data from the Phase 3 VISIONARY trial indicate that Voyxact (sibeprenlimab-szsi) may significantly slow progression of primary immunoglobulin A nephropathy (IgAN), preserving kidney function and reducing the likelihood…
Otsuka has claimed a significant victory in the increasingly competitive immunoglobulin A nephropathy (IgAN) field with FDA accelerated approval of Voyxact, the first-in-class anti-APRIL biologic therapy designed to treat this…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
